Brief: Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
06/12/2023 13:05
Dec 6 (Reuters) - Century Therapeutics Inc IPSC.O :
* CENTURY THERAPEUTICS RECEIVES FDA CLEARANCE OF IND
APPLICATION
FOR CNTY-101 IN SYSTEMIC LUPUS ERYTHEMATOSUS
* CENTURY THERAPEUTICS INC- PLANS TO INITIATE PHASE 1
CLINICAL
TRIAL IN FIRST HALF OF 2024; INITIAL DATA EXPECTED BY YEAR-END
2024
Source text for Eikon: ID:nGNX5MwsMP
Further company coverage: IPSC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Century Therapeutics
See all newsCentury Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Century Therapeutics Q2 net loss misses estimates on lease termination loss
Brief: Century Therapeutics Q2 Net Income USD -34.55 Million Vs. IBES Estimate USD -22.4 Million
Century Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Century Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview